-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Applied DNA to Showcase Linea(TM) DNA and Linea(TM) IVT Platforms at 24th Annual World Vaccine Congress
Applied DNA to Showcase Linea(TM) DNA and Linea(TM) IVT Platforms at 24th Annual World Vaccine Congress
STONY BROOK, NY / ACCESSWIRE / March 14, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, will showcase its Linea IVT and Linea DNA platforms at the 24th Annual World Vaccine Congress, which will be held April 1 - 4, 2024. Applied DNA sales team members will be available during the Congress for one-on-one meetings.
Location: | Walter E. Washington Convention Center, Washington, D.C. |
Tickets: | Visit the conference website. |
Schedule a meeting: link
About the Linea DNA and Linea IVT Platforms
The Linea DNA platform is a completely cell-free DNA production platform founded on Applied DNA's long-standing expertise in the large-scale enzymatic production of DNA. Capable of producing DNA in quantities ranging from milligrams to grams, the Linea DNA platform can produce high-fidelity DNA constructs ranging from 100bp to 20kb in size. The DNA produced via the Linea DNA platform is free of the adventitious DNA sequences found in other sources of DNA, is rapidly scalable, and provides for simple chemical modification of DNA constructs.
The Linea IVT platform combines DNA IVT templates manufacturing via the Linea DNA platform with a proprietary Linea RNAP to enable mRNA and sa-mRNA manufacturers to produce what Applied DNA believes to be better mRNA faster, with advantages over conventional mRNA production, including: 1) the elimination of plasmid DNA as a starting material; 2) the prevention or reduction of dsRNA contamination; and 3) simplified mRNA production workflows.
About Applied DNA Sciences
Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we operate in three primary business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and, through our recent acquisition of Spindle Biotech, Inc. ("Spindle"), the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services; and (iii) the manufacture and detection of DNA for industrial supply chain security services.
Visit adnas.com for more information. Follow us on X and LinkedIn. Join our mailing list.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be "forward-looking" in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA's future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, unknown future demand for its biotherapeutics products and services, the inherent risk and unknown outcome of research and development projects, the unknown amount of revenues and profits that will result from the Linea DNA and/or Linea IVT platforms, the fact that there has never been a commercial drug product utilizing PCR-produced DNA technology and/or the Linea IVT or Linea DNA platforms approved for human therapeutic use, our need to raise substantial additional funds, and various other factors detailed from time to time in Applied DNA's SEC reports and filings, including its Annual Report on Form 10-K, as amended, filed on December 7, 2023, and Quarterly Report on Form 10-Q filed on February 8, 2024, and other reports it files with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events unless otherwise required by law.
Contacts:
Applied DNA Sciences
Investor Relations contact: Sanjay M. Hurry, 917-733-5573, sanjay.hurry@adnas.com
Web:
Twitter: @APDN
###
SOURCE: Applied DNA Sciences, Inc.
STONY BROOK, NY / ACCESSWIRE / March 14, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, will showcase its Linea IVT and Linea DNA platforms at the 24th Annual World Vaccine Congress, which will be held April 1 - 4, 2024. Applied DNA sales team members will be available during the Congress for one-on-one meetings.
紐約州石溪/ACCESSWIRE/2024年3月14日/基於聚合酶鏈反應的DNA技術的領導者應用DNA科學公司(納斯達克股票代碼:APDN)(應用DNA)將在第24次會議上展示其Linea IVT和Linea DNA平台第四 年度世界疫苗大會,將於2024年4月1日至4日舉行。應用DNA銷售團隊成員將在大會期間參加一對一的會議。
Location: |
Walter E. Washington Convention Center, Washington, D.C. |
Tickets: |
Visit the conference website. |
地點: |
華盛頓特區沃爾特·華盛頓會議中心 |
門票: |
訪問會議網站。 |
Schedule a meeting: link
安排會議:鏈接
About the Linea DNA and Linea IVT Platforms
關於 Linea DNA 和 Linea IVT 平台
The Linea DNA platform is a completely cell-free DNA production platform founded on Applied DNA's long-standing expertise in the large-scale enzymatic production of DNA. Capable of producing DNA in quantities ranging from milligrams to grams, the Linea DNA platform can produce high-fidelity DNA constructs ranging from 100bp to 20kb in size. The DNA produced via the Linea DNA platform is free of the adventitious DNA sequences found in other sources of DNA, is rapidly scalable, and provides for simple chemical modification of DNA constructs.
Linea DNA平台是一個完全無細胞的DNA生產平台,其基礎是應用DNA在大規模酶促生產DNA方面的長期專業知識。Linea DNA平台能夠生成從毫克到克不等的DNA,可以生成大小從100bp到20kb不等的高保真DNA結構。通過Linea DNA平台產生的DNA不含其他DNA來源中的不確定DNA序列,可快速擴展,並且可以對DNA結構進行簡單的化學修飾。
The Linea IVT platform combines DNA IVT templates manufacturing via the Linea DNA platform with a proprietary Linea RNAP to enable mRNA and sa-mRNA manufacturers to produce what Applied DNA believes to be better mRNA faster, with advantages over conventional mRNA production, including: 1) the elimination of plasmid DNA as a starting material; 2) the prevention or reduction of dsRNA contamination; and 3) simplified mRNA production workflows.
Linea IVT平台將通過Linea DNA平台製造的DNA IVT模板與專有的Linea RNAP相結合,使mRNA和sa-mRNA製造商能夠更快地生產出應用DNA認爲更好的mRNA,具有與傳統mRNA生產相比的優勢,包括:1)消除質粒DNA作爲起始材料;2)預防或減少dsRNA污染;以及3)簡化mRNA的生產。
About Applied DNA Sciences
關於應用 DNA 科學
Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we operate in three primary business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and, through our recent acquisition of Spindle Biotech, Inc. ("Spindle"), the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services; and (iii) the manufacture and detection of DNA for industrial supply chain security services.
應用DNA Sciences是一家生物技術公司,開發生產和檢測脫氧核糖核酸(“DNA”)的技術。使用聚合酶鏈反應(“PCR”)來實現DNA的生產和檢測,我們在三個主要業務市場開展業務:(i)酶促製造用於生產基於核酸的療法的合成DNA,以及通過我們最近收購Spindle Biotech, Inc.(“Spindle”),開發和銷售用於生產mRNA的專有RNA聚合酶(“RNAP”)(ii) 在分子診斷和基因檢測服務中檢測 DNA 和 RNA;以及 (iii) 製造和檢測工業供應鏈安全服務的 DNA。
Visit adnas.com for more information. Follow us on X and LinkedIn. Join our mailing list.
訪問adnas.com了解更多信息。在 X 和 LinkedIn 上關注我們。加入我們的郵件列表。
Forward-Looking Statements
前瞻性陳述
The statements made by Applied DNA in this press release may be "forward-looking" in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA's future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, unknown future demand for its biotherapeutics products and services, the inherent risk and unknown outcome of research and development projects, the unknown amount of revenues and profits that will result from the Linea DNA and/or Linea IVT platforms, the fact that there has never been a commercial drug product utilizing PCR-produced DNA technology and/or the Linea IVT or Linea DNA platforms approved for human therapeutic use, our need to raise substantial additional funds, and various other factors detailed from time to time in Applied DNA's SEC reports and filings, including its Annual Report on Form 10-K, as amended, filed on December 7, 2023, and Quarterly Report on Form 10-Q filed on February 8, 2024, and other reports it files with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events unless otherwise required by law.
根據1933年《證券法》第27A條、1934年《證券交易法》第21E條和1995年《私人證券訴訟改革法》的定義,Applied DNA在本新聞稿中發表的聲明在本質上可能是 “前瞻性” 的。前瞻性陳述描述了Applied DNA的未來計劃、預測、戰略和預期,這些陳述基於假設,涉及許多風險和不確定性,其中許多是應用DNA無法控制的。由於其淨虧損的歷史、有限的財政資源、對其生物療法產品和服務的未來需求未知、研發項目的固有風險和未知結果、Linea DNA和/或Linea IVT平台將產生的收入和利潤金額未知、從未有過使用PCR生產的DNA技術和/或Linea IVT或Linea DNA的商用藥品,實際結果可能與預測存在重大差異獲准用於人類治療的平台,我們需要籌集大量額外資金,以及Applied DNA在美國證券交易委員會報告和文件中不時詳述的各種其他因素,包括2023年12月7日提交的經修訂的10-K表年度報告和2024年2月8日提交的10-Q表季度報告,以及其向美國證券交易委員會提交的其他報告,這些報告可在www.sec.gov上查閱。除非法律另有規定,否則Applied DNA沒有義務公開更新任何前瞻性陳述以反映本文發佈之日之後的新信息、事件或情況,也沒有義務反映意外事件的發生。
Contacts:
聯繫人:
Applied DNA Sciences
Investor Relations contact: Sanjay M. Hurry, 917-733-5573, sanjay.hurry@adnas.com
Web:
Twitter: @APDN
應用 DNA 科學
投資者關係聯繫人:Sanjay M. Hurry,917-733-5573,sanjay.hurry@adnas.com
網頁:
推特:@APDN
###
###
SOURCE: Applied DNA Sciences, Inc.
來源:應用DNA科學公司
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧